Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab and Zanubrutinib in Newly Diagnosed CLL/SLL (TaZa CLL Study)
NCT05718869Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- May 2023
- Primary completion
- Jul 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab, zanubrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by City of Hope. Started May 2023; status: active, not recruiting.
02
Drugs
tafasitamabzanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05718869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718869.